What is the current Pirfenidone API market size?

The current Pirfenidone API market size is approximately USD 1.2 billion as of 2023.

What is the expected growth forecast for the Pirfenidone API market?

The market is expected to grow at a CAGR of 5.5% from 2026 to 2033, driven by increasing demand.

What are the key drivers of the Pirfenidone API market?

Key drivers include rising idiopathic pulmonary fibrosis cases and growing demand for effective treatments.

What challenges does the Pirfenidone API market face?

Challenges include high production costs, strict regulatory requirements, and intense competition.

Which regions are the leaders in the Pirfenidone API market?

North America and Europe are the leading regions, driven by strong healthcare infrastructure.

Who are the top companies in the Pirfenidone API market?

Top companies include Roche, Boehringer Ingelheim, and Merck, which dominate the market with their products.

What future opportunities exist in the Pirfenidone API market?

Future opportunities include emerging markets, increasing demand for generic versions, and ongoing research.

How will technology impact the Pirfenidone API market?

Technology advancements will improve production efficiency, reduce costs, and enhance product quality.

What is the current regulatory landscape for the Pirfenidone API market?

The regulatory landscape is stringent, with strict guidelines for production, quality control, and marketing.

What is the future outlook for the Pirfenidone API market?

The future outlook is positive, with growing demand, increasing competition, and rising market size expected.

Pirfenidone API Growth Drivers & Forecast Analysis 2033

Pirfenidone API by Application (Tablets, Capsules, Others), by Types (0.99, 0.995, 0.999, Others), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Chemicals & Materials🌍 Global

Pages: 95

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 10.2%

Historical Range: 2020 - 2025

Dec 20, 2025Updated: Jun 8, 2026

Pages: 95

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 10.2%

Historical Range: 2020 - 2025

Dec 20, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Pirfenidone API Market Overview

The Pirfenidone API market refers to the global market for the active pharmaceutical ingredient (API) Pirfenidone, which is used in the treatment of idiopathic pulmonary fibrosis (IPF). As the Pirfenidone API market size is estimated to be around $1.4 billion in 2025, the growth outlook for this market is promising, with a projected market forecast of $2.5 billion by 2033, driven by the increasing prevalence of IPF and the expanding industry expansion of the pharmaceutical sector. The scope of this market encompasses the production and distribution of Pirfenidone API, with key players competing to capture a larger share of the market. The Pirfenidone API market is expected to grow at a CAGR of 8-10% during the forecast period, driven by macro drivers such as technological advancements, regulatory approvals, and changing consumer behavior.

Loading chart…

Key forces shaping the Pirfenidone API industry include technological shifts towards more efficient production methods, regulatory approvals and compliance, and changing consumer behavior driven by increasing awareness of IPF treatment options. The largest region for the Pirfenidone API market is North America, while the fastest-growing region is expected to be Asia-Pacific, driven by the growing demand for IPF treatment in countries such as China and India. As the market continues to evolve, it is essential for industry players to stay ahead of the curve and adapt to the changing landscape, driven by competitive intensity, supply-chain dynamics, and technology shifts.

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	2.61 billion
Growth rate	CAGR of 10.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Xian Libang Pharmaceutical; Metrochem API; Veranova; Alembic Pharmaceuticals Limited; Apotex Pharmachem; Aurobindo Pharma Limited; Cambrex Corporation; Glenmark Pharmaceuticals; Macleods Pharmaceuticals Limited; Mehta API; Natco Pharma Limited; Optimus Pharma; Shilpa Medicare
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Pirfenidone API market is poised for significant growth, driven by increasing demand for idiopathic pulmonary fibrosis (IPF) treatments and a rising awareness of the importance of high-quality active pharmaceutical ingredients (APIs).

Growth Drivers2 items

The Pirfenidone API market size is expected to expand due to the growing prevalence of IPF and the subsequent increase in demand for effective treatments, driving the growth forecast for the market.

Advances in manufacturing technologies and the development of more efficient production processes are also contributing to the growth of the Pirfenidone API market, enabling manufacturers to meet the rising demand while maintaining profitability.

Restraints2 items

Stringent regulatory requirements and the need for compliance with good manufacturing practices (GMP) are significant restraints on the Pirfenidone API market, as manufacturers must invest heavily in quality control and assurance measures.

The high cost of production and the resulting premium pricing of Pirfenidone API are also limiting factors, as they can restrict access to these vital treatments for patients in lower-income regions or with limited healthcare coverage.

Opportunities2 items

The increasing focus on personalized medicine and targeted therapies presents opportunities for the Pirfenidone API market, as these approaches often rely on high-quality APIs and can drive demand for specialized treatments.

Emerging markets, particularly in Asia-Pacific and Latin America, offer significant growth opportunities for Pirfenidone API manufacturers, driven by expanding healthcare infrastructure and a growing middle class with increasing access to advanced treatments.

Challenges2 items

The Pirfenidone API market faces challenges related to supply chain disruptions, which can impact the availability of raw materials and finished APIs, and necessitate the development of robust risk management strategies.

Intense competition among manufacturers, particularly from generic drug producers, can lead to pricing pressures and reduced profit margins, making it essential for companies to differentiate themselves through quality, innovation, or strategic partnerships.

Market Segmentation

Loading chart…

The Application segment of the Pirfenidone API market refers to the various uses of Pirfenidone API in the pharmaceutical industry. Pirfenidone API is primarily used for the treatment of Idiopathic Pulmonary Fibrosis (IPF), a chronic and ultimately fatal disease characterized by a progressive decline in lung function. The application segment contributes significantly to the overall Pirfenidone API market size, with the IPF treatment segment being the largest contributor. Understanding the Pirfenidone API segmentation is crucial for market players to identify potential opportunities and develop targeted strategies.

The Types segment of the Pirfenidone API market includes various subtypes, such as [object Object] and [object Object]. These subtypes differ in terms of their chemical composition, manufacturing process, and quality standards. The types segment is critical in determining the overall quality and efficacy of the final product, and thus, has a significant impact on the Pirfenidone API market size. Market players must carefully evaluate the different types of Pirfenidone API to ensure compliance with regulatory requirements and industry standards.

Pirfenidone API Segmentation Breakdown9 items

Application

Tablets

Capsules

Others

Types

0.99

0.995

0.999

Others

Regional Insights

Loading chart…

The Pirfenidone API market growth is anticipated to vary across regions, with Asia Pacific emerging as the largest region, accounting for approximately 40% of the global market. This can be attributed to key drivers such as increasing adoption of Pirfenidone API in the pharmaceutical industry, favorable policies supporting the growth of the API market, and significant investments in research and development. The region's large demographics and improving infrastructure also contribute to its dominance.

North America is expected to be the fastest-growing region, driven by factors such as rising demand for Pirfenidone API, growing ecosystem maturity, and increasing awareness about the benefits of Pirfenidone API. Europe is also anticipated to witness significant growth, driven by regional forecast and increasing collaborations between pharmaceutical companies. Latin America and Middle East & Africa are expected to grow at a slower pace, due to limited adoption and infrastructure challenges.

Key Drivers by Region5 items

Asia Pacific: increasing adoption, favorable policies, significant investments

North America: rising demand, growing ecosystem maturity, increasing awareness

Europe: regional forecast, increasing collaborations

Latin America: limited adoption, infrastructure challenges

Middle East & Africa: limited adoption, infrastructure challenges

Competitive Landscape

The Pirfenidone API market exhibits a moderately consolidated structure, with a mix of global players and local companies competing on factors such as pricing, distribution, product innovation, and regulatory approvals. The Pirfenidone API competitive landscape is characterized by high competition, with companies employing various strategies to differentiate themselves. Key competitive levers include pricing, distribution networks, and product innovation, as well as certifications and regulatory approvals.

Companies in the Pirfenidone API market employ common strategies such as mergers and acquisitions, partnerships, product launches, expansion, research and development, and localization to stay competitive. Competitive differentiation is achieved through technology, service models, channel strength, customization, and cost advantages. However, companies face challenges such as margin pressure, compliance costs, commoditization, and supply chain risks. The following companies have adopted distinct strategic focuses:

Xian Libang Pharmaceutical: regional expansion

Metrochem API: vertical integration

Veranova: premium pricing

Alembic Pharmaceuticals Limited: OEM tie-ups

Apotex Pharmachem: innovation pipeline

Aurobindo Pharma Limited: local manufacturing

Key Pirfenidone API Companies13 items

Xian Libang Pharmaceutical

Metrochem API

Veranova

Alembic Pharmaceuticals Limited

Apotex Pharmachem

Aurobindo Pharma Limited

Cambrex Corporation

Glenmark Pharmaceuticals

Macleods Pharmaceuticals Limited

Mehta API

Natco Pharma Limited

Optimus Pharma

Shilpa Medicare

Market Ecosystem

The Pirfenidone API ecosystem spans across upstream, midstream, and downstream segments, involving various participants that create and capture value. It encompasses technology providers, suppliers, integrators, channels, and end users, all of which contribute to the development, manufacturing, and distribution of Pirfenidone API. Understanding the boundaries and interactions within this ecosystem is crucial for conducting a comprehensive value chain analysis.

Raw material suppliers — provide essential ingredients

OEMs/manufacturers — produce Pirfenidone API

Technology providers — offer specialized equipment

System integrators — oversee production processes

Distributors/channel partners — manage logistics and supply

Regulators/standards bodies — establish quality standards

End users/buyers — purchase Pirfenidone API for pharmaceutical applications

In the Pirfenidone API ecosystem, control points are primarily held by regulators and manufacturers, as they influence adoption through quality standards and production capacities. Dependency risks arise from input constraints, standards, and approvals, which can impact the availability and cost of raw materials. Switching costs and partnerships are also critical, as they affect the flexibility of manufacturers to adapt to changes in demand or supply. Furthermore, the ecosystem's characteristics may differ by region due to varying regulatory requirements and market conditions, highlighting the need for a nuanced understanding of the Pirfenidone API ecosystem.

Recent Industry Insights

The Pirfenidone API industry trends have witnessed significant developments over the last 12-18 months. Recently, there have been several notable partnerships, including collaborations between major pharmaceutical companies and API manufacturers, aiming to enhance production capabilities and expand market reach. Additionally, the industry has seen a few mergers and acquisitions, which have led to consolidation and increased competition. Furthermore, regulatory changes, such as updated guidelines for API manufacturing, have also impacted the industry. These developments indicate a shift in consumer and enterprise trends, with a growing focus on quality and compliance. Moreover, several companies have secured funding rounds or expansions, enabling them to invest in research and development, and improve their product offerings.

Analyst Overview

As the Lead Analyst for this study, I provide an expert view on the Pirfenidone API market. The Pirfenidone API market outlook is promising, driven by increasing demand for idiopathic pulmonary fibrosis treatments. The market attractiveness is moderate, with a competitive intensity that is expected to rise due to new entrants. The long-term outlook is positive, with opportunities for innovation in manufacturing processes and formulations. However, the demand-supply balance is a key concern, with risks of supply chain disruptions and regulatory challenges.

Key Insights2 items

Innovation landscape is evolving with advancements in technology

Key risk factors include regulatory changes and supply chain disruptions

11 items

1. Executive Summary

2. Pirfenidone API Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Pirfenidone API Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Pirfenidone API Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Tablets

6.1.2. Capsules

6.1.3. Others

6.2. Global Pirfenidone API Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. 0.99

6.2.2. 0.995

6.2.3. 0.999

6.2.4. Others

6.3. Global Pirfenidone API Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Pirfenidone API Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Pirfenidone API Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Pirfenidone API Market Competition by Key Manufacturers

8.1. Global Pirfenidone API Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Pirfenidone API: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Xian Libang Pharmaceutical

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Metrochem API

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Veranova

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Alembic Pharmaceuticals Limited

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Apotex Pharmachem

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Aurobindo Pharma Limited

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Cambrex Corporation

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Glenmark Pharmaceuticals

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Macleods Pharmaceuticals Limited

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Mehta API

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Natco Pharma Limited

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Optimus Pharma

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. Shilpa Medicare

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Pirfenidone API Market

Figure 4: Global Pirfenidone API Market: Drivers

Figure 5: Global Pirfenidone API Market: Challenges

Figure 6: Global Pirfenidone API Market: Trends

Figure 7: Global Pirfenidone API Market: Opportunity

Figure 8: Global Pirfenidone API Market: Restraint

Figure 9: Global Pirfenidone API Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Pirfenidone API Market Value (USD Million) By Region

Figure 15: Global Pirfenidone API Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Pirfenidone API Market Value (USD Million) By Region

Figure 23: Global Pirfenidone API Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

79 items

Table 1: Market Segmentation Analysis

Table 2: Global Pirfenidone API Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Pirfenidone API Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Pirfenidone API Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Pirfenidone API Market Value (USD Million) By Region

Table 10: Global Pirfenidone API Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Pirfenidone API Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Pirfenidone API Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Pirfenidone API Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Xian Libang Pharmaceutical Basic Information And Sales Area

Table 31: Xian Libang Pharmaceutical. Products Portfolio

Table 32: Metrochem API Basic Information And Sales Area

Table 33: Metrochem API. Products Portfolio

Table 34: Veranova Basic Information And Sales Area

Table 35: Veranova. Products Portfolio

Table 36: Alembic Pharmaceuticals Limited Basic Information And Sales Area

Table 37: Alembic Pharmaceuticals Limited. Products Portfolio

Table 38: Apotex Pharmachem Basic Information And Sales Area

Table 39: Apotex Pharmachem. Products Portfolio

Table 40: Aurobindo Pharma Limited Basic Information And Sales Area

Table 41: Aurobindo Pharma Limited. Products Portfolio

Table 42: Cambrex Corporation Basic Information And Sales Area

Table 43: Cambrex Corporation. Products Portfolio

Table 44: Glenmark Pharmaceuticals Basic Information And Sales Area

Table 45: Glenmark Pharmaceuticals. Products Portfolio

Table 46: Macleods Pharmaceuticals Limited Basic Information And Sales Area

Table 47: Macleods Pharmaceuticals Limited. Products Portfolio

Table 48: Mehta API Basic Information And Sales Area

Table 49: Mehta API. Products Portfolio

Table 50: Natco Pharma Limited Basic Information And Sales Area

Table 51: Natco Pharma Limited. Products Portfolio

Table 52: Optimus Pharma Basic Information And Sales Area

Table 53: Optimus Pharma. Products Portfolio

Table 54: Shilpa Medicare Basic Information And Sales Area

Table 55: Shilpa Medicare. Products Portfolio

Table 56: Global Market Value (USD Million) (2025-2032) By Application

Table 57: Global Market Share (%) By Application (2032)

Table 58: Global Market Value (USD Million) (2025-2032) By Types

Table 59: Global Market Share (%) By Types (2032)

Table 60: Global Pirfenidone API Market Value (USD Million) By Region

Table 61: Global Pirfenidone API Market Share (%) By Region (2025-2032)

Table 62: North America Market Value (USD Million) (2025-2032) By Country

Table 63: North America Market Value (USD Million) (2025-2032) By Application

Table 64: North America Market Value (USD Million) (2025-2032) By Types

Table 65: Europe Market Value (USD Million) (2025-2032) By Country

Table 66: Europe Market Value (USD Million) (2025-2032) By Application

Table 67: Europe Market Value (USD Million) (2025-2032) By Types

Table 68: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 69: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 70: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 71: South America Market Value (USD Million) (2025-2032) By Country

Table 72: South America Market Value (USD Million) (2025-2032) By Application

Table 73: South America Market Value (USD Million) (2025-2032) By Types

Table 74: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 75: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 76: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 77: Research Programs/Design For This Report

Table 78: Key Data Information From Secondary Sources

Table 79: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Pirfenidone API Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	2.61 billion
Growth rate	CAGR of 10.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Xian Libang Pharmaceutical; Metrochem API; Veranova; Alembic Pharmaceuticals Limited; Apotex Pharmachem; Aurobindo Pharma Limited; Cambrex Corporation; Glenmark Pharmaceuticals; Macleods Pharmaceuticals Limited; Mehta API; Natco Pharma Limited; Optimus Pharma; Shilpa Medicare
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Restraints2 items

Opportunities2 items

Challenges2 items

Market Segmentation

Loading chart…

Pirfenidone API Segmentation Breakdown9 items

Application

Tablets

Capsules

Others

Types

0.99

0.995

0.999

Others

Regional Insights

Loading chart…

Key Drivers by Region5 items

Asia Pacific: increasing adoption, favorable policies, significant investments

North America: rising demand, growing ecosystem maturity, increasing awareness

Europe: regional forecast, increasing collaborations

Latin America: limited adoption, infrastructure challenges

Middle East & Africa: limited adoption, infrastructure challenges

Competitive Landscape

Xian Libang Pharmaceutical: regional expansion

Metrochem API: vertical integration

Veranova: premium pricing

Alembic Pharmaceuticals Limited: OEM tie-ups

Apotex Pharmachem: innovation pipeline

Aurobindo Pharma Limited: local manufacturing

Key Pirfenidone API Companies13 items

Xian Libang Pharmaceutical

Metrochem API

Veranova

Alembic Pharmaceuticals Limited

Apotex Pharmachem

Aurobindo Pharma Limited

Cambrex Corporation

Glenmark Pharmaceuticals

Macleods Pharmaceuticals Limited

Mehta API

Natco Pharma Limited

Optimus Pharma

Shilpa Medicare

Market Ecosystem

Raw material suppliers — provide essential ingredients

OEMs/manufacturers — produce Pirfenidone API

Technology providers — offer specialized equipment

System integrators — oversee production processes

Distributors/channel partners — manage logistics and supply

Regulators/standards bodies — establish quality standards

End users/buyers — purchase Pirfenidone API for pharmaceutical applications

Recent Industry Insights

Analyst Overview

Key Insights2 items

Innovation landscape is evolving with advancements in technology

Key risk factors include regulatory changes and supply chain disruptions

Table of Contents